今天BMS与Infinity联合宣布
合作开展Nivolumab联合IPI-549
用于治疗晚期尿路上皮癌临床研究
即
铂类方案治疗进展的晚期尿路上皮癌
Nivolumab为已经获批的二线治疗产品
IPI-549为唯一的临床在研PI3K-γ选择性抑制剂
该研究代号MARIO-275
临床II期试验
计划招募150位受试者
试验分为Nivo+IPI-549/Nivo单药组
首要研究终点为ORR
包括
所有患者以及不同MDSCs的基线水平亚组
The expansion of our relationship with Infinity underscores our efforts to follow the science and support potential novel combination therapies in immuno-oncology for cancer patients with limited treatment options. Our goal is to determine whether targeting the tumor microenvironment with IPI-549 will enhance the activity of Opdivo for people with urothelial cancer and potentially in other tumor types where MDSCs suppress the immune response.
Head of Oncology Development, Bristol-Myers Squibb
CheckMate-275临床中
高MDSCs水平患者给予Opdivo治疗后
总生存期相应缩短
而此前联合的I期临床MARIO-1也显示
IPI-549可以降低MDSCs水平
二者联合可能会出现协同机制
